0
Skip to Content
Context Therapeutics
Who We Are
Our Technology
Pipeline
CTIM-76
CT-202
Patients
Careers
Investors & News
Context Therapeutics
Who We Are
Our Technology
Pipeline
CTIM-76
CT-202
Patients
Careers
Investors & News
Who We Are
Folder: Our Science
Back
Our Technology
Pipeline
CTIM-76
CT-202
Patients
Careers
Investors & News

Development of CTIM-76, a highly specific Claudin 6 bispecific antibody for treatment of ovarian cancer

Publications
Apr 20
Written by Martin Lehr
2023_AACR_MPS CLDN6 bispecifics1024_1.jpg
CLDN6
Martin Lehr
Previous
Previous

CTIM-76, a Highly Specific Claudin 6 Antibody
Next
Next

Atomic-level Specificity of Claudin 6 Monoclonal Antibodies Isolated for Treating Solid Tumors

About Us
Leadership
Partnering
Contact Us

Our Technology
Pipeline
CTIM-76
CT-202

Patients
Clinical Trials
Expanded Access Policy
Investigator Led Trials

Investors & Media
News
Publications

Careers
Open Positions

Privacy Policy          Terms of Use

© Context Therapeutics Inc. 2026  |  All Rights Reserved